# S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma

> **NCT00005834** · PHASE3 · TERMINATED · sponsor: **SWOG Cancer Research Network** · enrollment: 19 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** cisplatin
- **DRUG:** cyclophosphamide
- **DRUG:** dexamethasone
- **DRUG:** etoposide
- **DRUG:** thalidomide

## Key facts

- **NCT ID:** NCT00005834
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2000-04
- **Primary completion:** 2003-11
- **Final completion:** 2007-11
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** poor accrual
- **Last updated:** 2015-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005834, "S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00005834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*